3
|
Extermann M, Boler I, O’Neill E, Brown R, Defelice J, Levine R, Lubiner E, Reyes P, Schreiber F, Lyman GH, Balducci L. Muscle weakness is a significant problem in older patients receiving chemotherapy. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.8545] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
8545 Background: Accurate prediction of toxicities from chemotherapy in the elderly could lead to improved decision making and supportive care. Methods: A large prospective multicentric cohort study of older cancer patients undergoing chemotherapy is underway to document the occurrence of chemotherapy toxicity and to develop a predictive score: the CRASH score (Chemotherapy Risk Assessment Score for High Age patients). Toxicity, including muscle weakness, is assessed using the Common Toxicity Criteria v.3.0. Results: An analysis of the first 200 patients entered in the study revealed an infrequently highlighted side effect: muscle weakness. Twenty patients were not evaluable for this analysis. Muscle weakness was reported by 22 patients. This represented 12.2% of the patients, of whom 13 (7.2%) had grade 3 muscle weakness. There was no grade 4 muscle weakness. This side effect appears to be independent from fatigue: only 4/22 patients reported concomitant severe (grade 3–4) fatigue, and among the 24 patients with severe fatigue, only 4 reported any muscle weakness. Muscle weakness occurred fairly early during the treatment: median 30 days (range 6–126 days). The muscle weakness was predominantly of two types: a generalized muscle weakness, or a weakness affecting the lower extremities. It was accompanied by falls in two patients. That weakness was present across tumor types, chemotherapy types, individual physicians, and oncology centers. Like the rest of the study population, the majority of these patients had advanced disease. Other frequent severe side effects were: grade 4 neutropenia 31.7%; grade 3–4: hypokalemia 8.8%, hyperglycemia 8.3%, hyponatremia 7.2%, febrile neutropenia 7.2%, diarrhea 7.2%, infection with neutropenia 6.7%. Conclusion: Muscle weakness is a frequent and clinically significant side effect of chemotherapy in the elderly, distinguishable from fatigue. This could be targeted by a preventive physical therapy intervention to prevent muscle deconditioning. [Table: see text]
Collapse
Affiliation(s)
- M. Extermann
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - I. Boler
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - E. O’Neill
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - R. Brown
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - J. Defelice
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - R. Levine
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - E. Lubiner
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - P. Reyes
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - F. Schreiber
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - G. H. Lyman
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| | - L. Balducci
- H. Lee Moffitt Cancer Center, Tampa, FL; Florida Cancer Specialists, Sarasota, FL; Powell Cancer Center, Clearwater, FL; Space Coast Medical Associates, Titusville, FL; Florida Cancer Specialists, Port Charlotte, FL; Lake Heart & Cancer Medical Center, Leesburg, FL; Center for Cancer Care and Research, Lakeland, FL; University of Rochester, Rochester, NY
| |
Collapse
|
4
|
Jacobsen PB, Shibata D, Siegel E, Lee J, Druta M, Marshburn J, Levine R, Gondi A, Defelice J, Malafa M. Measuring quality of care in the treatment of colorectal cancer: The Moffitt Network Initiative on Practice Quality (MNIPQ). J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6001 Background: As the first step in a larger effort to improve quality of care among its member institutions, the MNIPQ sought to develop and implement methods to assess quality of care in the treatment of colorectal cancer. The current report focuses on our initial experience conducting quality assessments at 4 of 20 member institutions. Methods: Medical chart reviews were conducted of all patients diagnosed with colon or rectal cancer in 2004 and seen by a medical oncologist at the Moffitt Cancer Center or at any of three affiliate institutions. Abstractors, who were trained and periodically monitored, conducted the reviews using a web-based abstraction tool. Abstraction focused on assessing adherence to quality indicators consistent with evidence-, consensus-, and regulatory-based guidelines. Variability in adherence across sites was evaluated by conducting Fisher’s exact tests. The 186 patients whose charts were reviewed were predominantly female (57%) and diagnosed with colon cancer (74%). Results: Adherence was consistently (p values>.05) high across all four study sites for: presence of a pathology report confirming malignancy (91–100%); evidence of staging based on established criteria (88–94%); documentation of discussion or referral for chemotherapy in cases of lymph node (colon and rectal cancer) or rectal wall (rectal cancer) involvement (89–100%); and presence of chemotherapy flow sheets (92–100%). Adherence was consistently (p values>.05) lower across sites for: performance of complete colon evaluation within 12 months of surgery (24–47%) and performance of CEA test before (48–74%) or in the 6 months after (56–82%) surgery or chemotherapy. Adherence varied significantly (p < .001) across sites only for documentation of consent for patients treated with chemotherapy (41–100%). Discussion: Findings identified several areas where efforts should be made to improve the quality of colorectal cancer care at one or more member institutions. In addition, the methods developed have laid the groundwork for future efforts to measure and improve quality of care for other cancers and among a larger number of member institutions. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. B. Jacobsen
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - D. Shibata
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - E. Siegel
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - J. Lee
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - M. Druta
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - J. Marshburn
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - R. Levine
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - A. Gondi
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - J. Defelice
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| | - M. Malafa
- Moffitt Cancer Center, Tampa, FL; Space Coast Medical Associates, Titusville, FL; Center for Cancer Care and Research, Lakeland, FL; Morton Plant Hospital, Clearwater, FL
| |
Collapse
|